American Journal of Psychiatry

Objective:About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective ...

https://doi.org/10.1176/appi.ajp.2019.19020172

pdf

abstract

full text

SAVE ARTICLE

Video

Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study

Publication date: 08 March 2019

Pages439–448

Objective:Cariprazine, a dopamine D₃/D₂ and 5-HT_1A receptor partial agonist, was found to be effective in treating bipolar I depression in a previous phase 2 study. This phase 3 study further assessed the efficacy, safety, and tolerability of cariprazine ...

https://doi.org/10.1176/appi.ajp.2018.18070824

AudioVideo

Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial

Publication date: 18 January 2019

Pages449–456

Objective:This study evaluated the benefits of olanzapine compared with placebo for adult outpatients with anorexia nervosa.Methods:This randomized double-blind placebo-controlled trial of adult outpatients with anorexia nervosa (N=152, 96% of whom were ...

https://doi.org/10.1176/appi.ajp.2018.18101125

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

Publication date: 08 March 2019

Pages457–467

Objective:Preclinical evidence and data from a proof-of-concept study in healthy volunteers suggest that samidorphan, an opioid antagonist, mitigates weight gain associated with olanzapine. This study prospectively compared combination therapy of ...

https://doi.org/10.1176/appi.ajp.2018.18030280

CME

Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [¹¹C]NOP-1A

Publication date: 06 May 2019

Pages468–476

Objective:Nociceptin/orphanin FQ (N/OFQ) is an antistress neuropeptide transmitter in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and anxiety symptoms during drug and alcohol withdrawal. It also inhibits the release of ...

https://doi.org/10.1176/appi.ajp.2019.18081007

CME

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism

Publication date: 29 March 2019

Pages477–486

Objective:Clozapine is the only effective medication for treatment-resistant schizophrenia, but its worldwide use is still limited because of its complex titration protocols. While the discovery of pharmacogenomic variants of clozapine metabolism may ...

https://doi.org/10.1176/appi.ajp.2019.18050589